{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-21-000444","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2021-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.173735+00:00","generated_at":"2026-06-28T18:48:09.459741+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Regen BioPharma settles convertible notes for $43,529 cash to avoid potential issuance of 855M shares","bullets":["Settled convertible notes principal of $29,836 and accrued interest of $26,227 for $43,529.30 cash.","Notes had a default conversion provision allowing conversion at 65% of lowest bid price during delinquency.","Company determined provision could permit conversion even after cure, enabling up to 855,584,615 shares worth $16.6M.","Settlement eliminates the default-conversion risk and potential massive dilution for existing shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-21-000444","json":"https://secwatch.observer/filing/0001607062-21-000444.json","markdown":"https://secwatch.observer/filing/0001607062-21-000444.md","text":"https://secwatch.observer/filing/0001607062-21-000444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000444/0001607062-21-000444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000444/rgbp102221form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T18:48:09.459741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}